alexa Could Pharmacogenomics Improve Efficacy and Safety of Trastuzumab?

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Could Pharmacogenomics Improve Efficacy and Safety of Trastuzumab?

Trastuzumab (Herceptin™) is a humanized anti-ErbB2 monoclonal antibody that has been approved for the treatment in the adjuvant and the metastatic setting of breast cancer patients that either overexpress ErbB2, or demonstrate ErbB2 gene amplification. An important serious adverse event associated with trastuzumab is the reduction of left heart ejection fraction resulting to congestive heart failure. The role of pharmacogenomics in breast cancer targeted treatment has been well recognized. However, data on the role of pharmacogenomics on the efficacy and safety of trastuzumab are still scarce.

 

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords